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The NS1 protein is the only nonstructural protein encoded by influenza A virus. It has been proposed that the NS1 performs
several regulatory functions during the viral replication cycle, including the regulation of synthesis, transport, splicing, and
translation of mRNAs. Through the use of reverse genetics, a viable transfectant influenza A virus (delNS1) which lacks the
NS1 gene has been generated. Our results indicate that the NS1 of influenza A virus is an auxiliary (virulence) factor which
plays a crucial role in inhibiting interferon-mediated antiviral responses of the host. © 1998 Academic Press
Influenza A viruses are important human pathogens
belonging to the group of Orthomyxoviridae. Their ge-
nome consists of eight different segments of negative
polarity which encode 10 viral proteins. All of the proteins
are structural proteins except for the NS1. The NS1 pro-
tein is an RNA-binding protein which has been impli-
cated in a number of regulatory functions during influ-
enza virus infection: (a) It inhibits host mRNA polyade-
nylation, which may contribute to the virus-induced
shutoff of host protein synthesis (1). (b) It binds to the
poly(A) tails of mRNAs and thus inhibits their nuclear
export (2, 3). (c) The NS1 has also been shown to inhibit
pre-mRNA splicing (2, 4) apparently by specifically bind-
ing U6 and U6atac snRNAs, which are key components
of the spliceosome (5, 6). (d) Binding of NS1 to dsRNA
prevents in vitro activation of the IFN-induced kinase
PKR suggesting a role of NS1 in preventing IFN-medi-
ated antiviral responses (7). (e) The NS1 protein has
been implicated in regulation of viral RNA polymerase
activity (8, 9). (f) It has also been shown that the NS1 is
able to stimulate the translation of specific viral mRNAs
(10, 11). (g) Finally, 3 host cell proteins, 2 nuclear and 1
cytoplasmic, have been reported to interact with the viral
NS1 protein (1, 12, 13). Most of the proposed functions of
the NS1 have been shown using in vitro systems or
expressing the protein in mammalian cells from a plas-
mid. In this communication, we describe the generation
of a recombinant influenza A/PR/8/34 virus lacking the
NS1 gene. This virus, delNS1, has a deletion in the NS
gene which eliminates the NS1 open reading frame ex-
cept for the first 10 amino acids which are shared with
the viral NEP (NS2) protein. The characterization of the
biological and molecular properties of the recombinant
delNS1 virus demonstrates that the NS1 protein of influ-
enza A virus is dispensable for viral replication in sub-
strates deficient in the IFN pathway, suggesting that this
protein is a virally encoded inhibitor of the IFN-mediated
antiviral responses.
Generation of the transfectant influenza virus delNS1,
lacking the NS1 gene
The NS-specific viral RNA segment of influenza A virus
encodes both the NS1 and the NEP proteins (14). Un-
spliced NS-specific mRNA translates into the NS1 pro-
tein, while the spliced RNA directs the synthesis of the
NEP. We have constructed plasmid pT3delNS1 which
expresses a mutated NS gene from influenza PR8 virus.
This mutated RNA segment contains a deletion of the
NS1-specific open reading frame (nt positions 57 to 528
of the PR8 NS gene) and thus it encodes only the NEP
(Fig. 1). RNP transfection of the delNS1 gene using the ts
25A-1 helper virus yielded a progeny virus which was
able to grow at 40°C in Vero cells. Amplification of the
NS gene of the rescued virus by RT-PCR confirmed the
substitution of the NS gene of the helper virus with that
derived from the transfected delNS1 gene (Fig. 1C).
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FIG. 1. Rescue of a transfectant influenza A virus (delNS1) lacking the NS1 gene. Schematic representations of the NS genes and NS-specific
mRNAs of (A) wild-type influenza A/PR/8/34 virus (WT NS) and (B) transfectant delNS1 influenza virus are shown. Genomic RNA segments are
represented as white boxes flanked by black squares. The latter represent the noncoding regions of the gene. NS-specific mRNAs are also
represented. Thin lines at the ends of the mRNAs represent untranslated regions. 59 cap structures (black circles) and poly(A) tails in the mRNAs are
shown. The open reading frame of the NS1 protein is represented as a gray box. The specific-NEP open reading frame is shown as a hatched box.
The NEP mRNA derived from the wild-type NS gene is a spliced product of the NS1 mRNA, as indicated by the V-shaped line. (C) RT-PCR analysis
of the NS RNA segment of delNS1 transfectant virus. The NS viral RNA from purified influenza A/PR/8/34 virus (wt) or from delNS1 virus (delNS1) was
amplified by coupled RT-PCR using the oligonucleotide primers described under Material and Methods. The PCR products were run on a 2% agarose
gel and stained with ethidium bromide. The positions of size markers are indicated on the right.
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Growth properties of delNS1 virus in tissue culture
and eggs
We compared the growth properties of delNS1 virus
and wild-type PR8 virus in Vero cells, MDCK cells, and
11-day-old embryonated chicken eggs. Cell monolayers
containing 106 Vero or MDCK cells were infected with
delNS1 virus or PR8 virus at multiplicity of infection
(m.o.i.) of approximately 0.001. Viral titers in the superna-
tants were measured by plaque assay on Vero cells at
12-h intervals during 3 days. DelNS1 virus was able to
grow in Vero cells to titers of 6 3 106 PFU/ml as com-
pared to a titer of 6 3 107 PFU/ml for wild-type PR8 virus
(Fig. 2). However, delNS1 virus replication was severely
reduced in MDCK cells and in 11-day-old embryonated
eggs. As shown in Fig. 2, delNS1 virus was only able to
grow to titers around 3 logs lower than those of wild-type
PR8 virus in MDCK cells. In addition, while PR8 virus
grew to hemagglutination (HA) titers of 2048 in embryo-
nated eggs, no HA titers were detected in eggs following
inoculation of 104 PFU of delNS1 virus (3 days at 37°C).
When a wild-type NS gene was reintroduced by trans-
fection in the delNS1 virus, the new “wild-type” virus was
able to grow in MDCK cells and in embryonated eggs to
titers similar to those of PR8 virus (data not shown). This
result demonstrates that the absence of the NS1 gene is
responsible for the altered growth properties of the
delNS1 virus.
Transfectant delNS1 virus is pathogenic in STAT12/2
mice
The reason for the differences between Vero cells,
MDCK cells, and embryonated eggs in supporting
delNS1 virus replication and viral protein expression may
relate to the inability of Vero cells to synthesize IFN (15).
In order to test this hypothesis, the ability of delNS1 virus
to replicate and cause disease in inbred mice and in
mice deficient in IFN responses was investigated. For
this purpose, we used 5 3 104 PFU of delNS1 virus to
infect intranasally (i.n.) five C57BL/6 mutant mice which
were homozygous for a targeted deletion of STAT1, a
transactivator required for IFN signaling (16, 17). Five
STAT11/1 C57BL/6 and four STAT11/1 BALB/c mice
were also inoculated with delNS1 virus. At day 4 postin-
fection, two STAT12/2 and two STAT11/1 C57BL/6
mice were sacrificed and viral titers were measured in
the lungs. STAT12/2 mice had viral titers of 2 3 103 and
4 3 103 PFU/lung. However, no virus (less than 102
PFU/lung) was detected in the lungs of STAT11/1 mice.
FIG. 2. Growth curves of delNS1 and PR8 viruses on Vero and MDCK cells. Confluent cell monolayers in 35-mm-diameter dishes were infected with
wild-type (wt) influenza A/PR/8/34 virus and with the transfectant delNS1 virus at an m.o.i. of 0.001. At the indicated time points, infectious particles
present in the media were titrated by plaque assay in Vero cells.
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By day 7 postinfection, all three remaining STAT12/2
mice died (Table 1). However, all STAT11/1 mice sur-
vived infection with delNS1 virus (Table 1) without show-
ing any symptoms of disease, as monitored by body
weight loss (data not shown). It should be noted that
wild-type PR8 virus is highly pathogenic for both
STAT11/1 and STAT12/2 mice and replicates to titers
of 104 to 105 PFU/lung in the lungs of both types of
animals (18).
Stimulation of transcription from an IFN-regulated
promoter by infection with transfectant delNS1 virus
In order to investigate if the deletion of the NS1 gene
in delNS1 virus results in an enhanced IFN response in
infected cells we performed transfection experiments
using pHISG54-1-CAT. This plasmid contains the CAT
reporter gene driven by the IFNa-stimulated promoter of
the ISG-54 K gene (19). As described under Materials
and Methods, 293 cells were transfected with pHISG54-
1-CAT and infected with delNS1 virus or wild-type PR8
virus at the indicated m.o.i.s. CAT activity in the infected
cell extracts was compared with that in uninfected cell
extracts. For positive control, transcription from the IFN-
regulated promoter was stimulated using poly(I–C) as a
source of dsRNA. No effect in reporter gene activity was
found when cells were transfected with pCAT3-control
vector containing the CAT gene under the control of an
SV40 promoter and infected at an m.o.i. of 0.05 with
delNS1 or wild-type virus (Fig. 3). However, infection at
an m.o.i. of 0.05 with delNS1 virus, but not with wild-type
virus, induced an approximately sixfold stimulation of the
reporter gene under the control of the IFN-regulated
TABLE 1
Survival of Mice Following delNS1 Virus Infectiona
Mice
Day postinfection
4 day 7 day 14 day
STAT12/2 C57BL/6 5 of 5 0 of 3b 0 of 3
STAT11/1 C57BL/6 5 of 5 3 of 3b 3 of 3
STAT11/1 BALB/c 4 of 4 4 of 4 4 of 4
a Mice under ether anesthesia were inoculated intranasally with 5 3
104 PFU of delNS1 virus.
b Two mice were sacrificed at day 4 to determine viral lung titers.
FIG. 3. Induction of transcription from an IFN-stimulated promoter by infection with delNS1 virus. Monolayers of 293 cells were transfected with
plasmid pHISG54-1-CAT encoding the reporter gene CAT under the control of a type I IFN-stimulated promoter or with pCAT3-control vector. One-day
postransfection, cells were transfected with 50 mg of dsRNA or infected with delNS1 virus or with wild-type influenza A/PR/8/34 virus (wt) at the
indicated m.o.i.s. One-day postinfection, CAT activity was determined in cell extracts. The stimulation of CAT activity following the different treatments
is indicated.
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promoter (Fig. 3). The transfectant virus lacking the NS1
gene was thus impaired in its ability to inhibit the IFN
response mounted by 293 cells following infection.
Discussion
Despite the conservation of the NS1 gene among all
influenza A virus isolates, and despite the presence of an
NS1 homologue in influenza B viruses, and probably also
in influenza C viruses, it was possible to rescue a viable
NS1-minus (delNS1) virus. Although the delNS1 virus
was able to grow in Vero cells, its ability to replicate was
severely reduced in MDCK cells and in 11-day-old em-
bryonated chicken eggs. In addition, levels of viral pro-
tein synthesis during one single replication cycle were
lower in MDCK cells than in Vero cells infected with
delNS1 virus (data not shown). Since Vero cells are
deficient in IFN expression (15), we suggest that the
altered tissue culture and egg growth of delNS1 virus is
due to IFN-mediated effects. The following evidence sup-
ports this hypothesis. (a) Infection with delNS1 virus
(m.o.i. of 0.05), but not with wild-type virus, induced
transactivation of an IFN-stimulated reporter gene in 293
cells. (b) The delNS1 virus was able to replicate and to
induce disease in mice that were deficient in IFN signal-
ing, i.e., STAT12/2 animals, but the virus was nonpatho-
genic in control mice. These results taken together
strongly suggest that one of the functions of the NS1
protein of influenza A virus is to inhibit IFN-mediated
antiviral responses of the host.
A possible mechanism by which the NS1 inhibits the
IFN-mediated antiviral responses is by binding (and se-
questering) dsRNA (20, 21). Influenza virus-infected cells
produce large amounts of negative sense RNA (vRNA) as
well as positive sense RNA (cRNA and mRNA) that can
form dsRNA. The presence of dsRNA has been shown to
lead to IFN secretion, resulting in the activation of tran-
scription of IFN-stimulated genes, including the genes
coding for the protein kinase PKR and the enzyme 29,59-
oligoadenylate synthetase. In addition, both PKR and
29,59 oligoadenylate synthetase are potently activated by
dsRNA at a posttranslational step, resulting in inhibition
of translation and in RNA degradation, respectively (22).
Interestingly, it has been reported that the NS1 protein
prevents the activation of PKR by dsRNA in vitro (7 ). It is
also noteworthy that an influenza virus containing a trun-
cated NS1 protein of only 80 amino acids, but not of 38
amino acids, is able to replicate in MDCK cells (23).
These findings suggest that only the amino-terminal
RNA-binding domain of the NS1 protein is required for
the inhibition of the IFN-mediated responses.
The importance of type I IFN as a potent host re-
sponse against viruses is illustrated by the fact that—as
a countermeasure—many viruses express IFN antago-
nists. Examples include VA RNAs of adenoviruses, the
Epstein–Barr virus-encoded structural small RNAs, the
K3L and E3L gene products of vaccinia virus, the NSP3
gene product of group C rotavirus, the s3 protein of
reovirus, the g(1)34.5 protein of HSV-1, and the NS5A
protein of hepatitis C virus, among others. Interestingly,
several of these viral products, like the NS1 protein of
influenza A virus, are able to bind to dsRNA and thus
prevent the activation of PKR (24, 25).
In addition to the inhibition of IFN-mediated re-
sponses, other functions have been proposed for the
NS1 protein of influenza viruses. Some of these func-
tions—such as the NS1-mediated stimulation of viral
mRNA translation (10, 11)—may result from indirect ef-
fects caused by the IFN inhibition. On the other hand, the
role of NS1 in inhibiting host mRNA polyadenylation,
mRNA nuclear export, and mRNA splicing may be due to
the direct interaction of NS1 with cellular components
involved in these processes (1–3, 5, 6, 13). Although the
deletion of the NS1 gene did not have dramatic effects
on the replication of the virus in Vero cells, the inability of
the NS1 knockout virus to perform some of the accessory
functions described above might be responsible for the
small (one log) difference in growth between delNS1 and
PR8 virus in Vero cells. In addition, the delNS1 virus not
only lacks the open reading frame for the NS1 protein but
it also expresses the NEP protein from an unspliced
mRNA (Fig. 1B). The fact that the delNS1 virus is viable
indicates that a mechanism of regulation of NEP expres-
sion based on splicing of the NS mRNA is not required
for the replication of the virus. However, at this point we
have not examined the precise time course for the ex-
pression of the NEP or the M2 proteins; thus, we cannot
exclude the possibility that the differential expression of
viral gene products other than the NS1 (partially) contrib-
utes to the altered phenotype of the virus. Further exper-
imentation will be required to clarify these aspects of the
replication cycle of the influenza virus.
Negative-strand RNA viruses have compact genomes
encoding a small number of viral proteins. Only recently
has it been possible to demonstrate that some of the
coding genes of this group of viruses are not essential.
For example, the use of reverse genetics techniques has
allowed the generation of replication-competent nega-
tive-strand RNA viruses lacking specific genes, such as
the genes encoding the C proteins of measles and ve-
sicular stomatitis viruses (26, 27), the V proteins of mea-
sles and Sendai viruses (28, 29), the SH protein of respi-
ratory syncytial virus (30), and the NS1 protein of influ-
enza A virus (this article). If proven to be adequately
attenuated and immunogenic in vivo, specific “gene
knockout” viruses could be used as live vaccines in
the future. Also, we postulate that some (or all) of the
negative-strand RNA viruses possess an auxiliary IFN
antagonist.
The genetic manipulation of the NS gene of influenza
A viruses may also help in generating viral vaccine vec-
tors which express novel antigens and/or polypeptides
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(31). Since the NS RNA segment is the shortest among
the eight viral RNAs, it is possible that the NS RNA will
tolerate longer insertions of heterologous sequences
than other viral RNAs. Moreover, the NS RNA segment
directs the synthesis of high levels of protein in infected
cells, suggesting that it would be an ideal segment for
the insertion of foreign antigens. However, further exper-
imentation is required to determine the ability of the NS
gene of influenza A viruses to support the expression of
foreign proteins.
Our results suggest that the IFN-antagonist function of
the NS1 protein of influenza A virus is one of the factors
involved in virus pathogenicity. It is thus possible that
highly pathogenic strains of influenza A virus have
evolved NS1 proteins which are more efficient in pre-
venting the IFN-mediated antiviral effects. In this respect,
we have recently shown that replication of wild-type
influenza A/WSN/33 virus is limited to the lungs of mice
by type I IFN, and that the virus becomes pantropic in
mice which are deficient in the IFN pathway (18). Thus,
one could speculate that influenza viruses containing
“better” NS1 proteins would be more virulent. An exam-
ple of a virus with a strong IFN-antagonist might be the
H1N1 virus of the 1918 influenza pandemic. The pres-
ence of a suboptimal NS1 protein in different influenza
virus strains would also explain why in some instances
influenza viruses appear to be good inducers of IFN (32).
Moreover, influenza viruses lacking the NS1 gene, such
as the delNS1 virus, may be even better IFN inducers
and thus could be used therapeutically to stimulate an
antiviral state against a variety of different infectious
agents. Finally, the function of the NS1 protein of influ-
enza A virus as an IFN-antagonist might be a good target
for novel antiviral compounds.
Materials and methods
Viruses, cells, and animals. Influenza A/PR/8/34 (PR8)
virus (H1N1) was propagated in 11-day-old embryonated
chicken eggs at 37°C. Influenza A virus 25A-1, a reas-
sortant virus containing the NS segment from the cold-
adapted strain A/Leningrad/134/47/57 and the remaining
genes from PR8 virus (33, 34), was grown in Vero cells at
34°C. The 25A-1 virus is ts in mammalian cells and was
used as helper virus for the rescue of the delNS1 trans-
fectant virus. Vero cells and MDCK cells were used for
influenza virus growth in the presence of 1 mg/ml of
trypsin (Difco Laboratories, Detroit, MI). In plasmid trans-
fection experiments 293 cells were used. C57BL/6 mice
homozygous for a targeted deletion of STAT1 were gen-
erated as previously described (16). Specific-pathogen-
free C57BL/6 and BALB/c mice were purchased from
Taconic Farms.
Animal infections. Female mice were used for influ-
enza virus infection at 4 to 6 weeks of age. i.n. inocula-
tions were performed in STAT11/1 and STAT12/2 mice
under ether anesthesia using 50 ml of MEM containing
varying amounts of delNS1 virus. Animals were moni-
tored daily and sacrificed when observed in extremis. All
procedures were in accord with NIH guidelines on care
and use of laboratory animals.
Plasmids. pT3delNS1 was made as follows. First,
pUC19-T3/NS PR8, containing the complete NS gene of
PR8 virus flanked by the T3 RNA polymerase promoter
and a BpuAI restriction site (23), was amplified by inverse
PCR using primers 59-CTGAAAGCTTGACACAGTGTTTG-39
and 59-GACATACTGCTGAGGATGTC-39 (CODON Genetic
Systems, Weiden, Austria). The obtained cDNA was
phosphorylated, Klenow treated, self-ligated, and propa-
gated in Escherichia coli strain TG1. The construct ob-
tained after purification was named pT3delNS1 and ver-
ified by sequencing. pHISG54-1-CAT (19) and pCAT3-
control vector (Promega, Madison, WI) encoded the CAT
reporter gene under the transcriptional control of the
IFNa-stimulated promoter of the ISG-54 K gene and of
the SV40 promoter, respectively.
Generation of transfectant viruses. Generation of
delNS1 virus was performed by ribonucleoprotein (RNP)
transfection (35). The RNPs were formed as previously
described (36). RNP complexes were transfected into
Vero cells which were previously infected with 25A-1
virus. Transfected cells were incubated for 18 h at 37°C,
and the supernatant was passaged twice in Vero cells at
40°C and plaque purified three times in Vero cells. The
isolated delNS1 virus was analyzed by RT-PCR using two
primers, one complementary to positions 1 to 21 at the 39
noncoding end of the NS gene, and the other containing
the last 38 nucleotides of the 59 noncoding end of the NS
gene.
CAT transfections. Monolayers of 293 cells in 35-mm
dishes were transfected with 1 mg of pHISG54-1-CAT or
1 mg of pCAT3-control vector using DOTAP lipofection
reagent (Boehringer Mannheim, Indianapolis, IN) ac-
cording to the manufacturer’s instructions. One-day pos-
transfection, cells were infected with delNS1 virus or PR8
virus at the indicated multiplicities of infection. As con-
trols, cells were mock-infected or transfected with 50 mg
of poly(I–C) (Sigma, St. Louis, MO). After 24 h at 37°C,
cell extracts were made and assayed for CAT activity, as
described (35).
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